Symposium Agenda

Reception, 5:30-7 p.m.

Whitaker Campus Commons

Welcome & Introductions, 7 p.m.

Hodson Auditorium, Rosenstock Hall

• Debbie Ricker, Ph.D.
  President, Hood College
• Ethan Dmitrovsky, M.D.
  Director, Frederick National Laboratory for Cancer Research

Keynote, 7:30 p.m.

"Reaching the 2030 SDG Target for AIDS: Success, Challenges and Prospects"
Salim S. Abdool Karim, Ph.D.
Director, Centre for AIDS Program of Research, South Africa (CAPRISA)
CAPRISA Professor of Global Health, Columbia University
Special Advisor to the Director-General of the World Health Organization
Pro Vice-Chancellor (Research), University of KwaZulu-Natal
Adjunct Professor of Medicine, Weill Medical College of Cornell University

Free and open to the public; registration required.

Session 1: Welcome & Distinguished Opening Plenary Lecture

• 7:30-8 a.m., Networking
  Continental breakfast will be provided.
• 8-8:15 a.m., Welcome
  Douglas Lowy, Principal Deputy Director, National Cancer Institute
• 8:15-9 a.m., HIV/AIDS: Then and Now
  Cliff Lane, Director of Clinical Research and Clinical Director, National Institute of Allergy and Infectious Diseases 
  (Introduced by Jeffrey Lifson, Director, AIDS and Cancer Virus Program)

NOTE:  As Dr. Anthony Fauci continues to make a full recovery from a bout of West Nile Fever virus, he regrets that he will be unable to deliver the originally scheduled Distinguished Opening Plenary Lecture to begin the Symposium. We send him our best wishes for a full recovery. We are honored that Dr. Clifford Lane, Director of Clinical Research and Clinical Director, National Institute of Allergy and Infectious Diseases, will deliver the Distinguished Opening Plenary Lecture. Dr. Lane, who was an active participant with Dr. Fauci in many of the key events and developments in HIV research and clinical care over the past several decades, will reflect on his experiences in HIV/AIDS in his lecture.

Session 2: Vaccine Prevention

Session Moderator: Barbara Felber, Senior Investigator, Vaccine Branch, Center for Cancer Research, National Cancer Institute

• 9:05-9:30 a.m., Mechanism for Evolution of Autologous Antibodies upon bnAb Therapy: Implications for Vaccination and Cure
  Arup K. Chakraborty,  John M. Deutch Institute Professor, Professor Chemical Engineering, Physics and Chemistry
  Massachusetts Institute of Technology
• 9:35-10 a.m., Pre-clinical Development of a Highly Networked T-Cell Vaccine for HIV Prevention and Therapy
  Gaurav D. Gaiha,  Principal Investigator and Group Leader, Ragon Institute of MGH, MIT and Harvard
• 10:05-10:30 a.m., Efficacy and Mechanisms of Unconventionally Restricted CMV-Vectored T-Cell Vaccines
  Louis J. Picker, Professor, VGTI-Vaccine and Gene Therapy Institute, Molecular Microbiology and Immunology Graduate Program, School of Medicine, Program in Molecular and Cellular Biosciences, School of Medicine, Oregon Health & Science University
• 10:30-10:45 a.m., Break
• 10:45-11:10 a.m., HIV Vaccine Immunogen Design for Induction of Broadly Neutralizing Antibodies
  Dennis Burton, Chair and Professor, Department of Immunology and Microbiology, Scripps Research Institute, Director, AIDS Vaccine Research IAVI Neutralizing Antibody Center
•  11:15-11:40 a.m., Systems Biological Assessment of the Mechanisms and Predictors of the Durability of Vaccine Responses
  Bali Pulendran, Violetta L. Horton Professor, Stanford University School of Medicine
• 11:45 a.m.-12:10 p.m., Engineering Innate Stimulation and Control of Vaccine Kinetics to Enhance HIV Vaccines
  Darrell Irvine, Underwood-Prescott Professor, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology
• 12:15-1:30 p.m., Lunch

Session 3: Non-Vaccine Prevention: bNAbs and Long-Acting Anti-Retrovirals

Session Moderator: Diane Bolton, Chief, Animal Models and Viral Persistence Laboratory, United States HIV Research Program

• 1:30-1:55 p.m., Lifelong Delivery of Monoclonal Antibodies using AAV Vectors 
  Ronald Desrosiers, Professor and Vice Chair, Department of Pathology, University of Miami Miller School of Medicine
• 2-2:25 p.m., Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis: State of the Science, Implementation, and Looking to the Future 
  Raphael J. Landovitz, Professor of Medicine, Interim Chief, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, Director, UCLA Center for Clinical AIDS Research & Education, Co-Director Center for HIV Identification, Prevention, and Treatment Services
• 2:30-2:55 p.m., Preclinical Evaluations of Long-acting Lenacapavir PrEP in Nonhuman Primates Challenged with Simian-tropic HIV-1
  Gregory Del Prete, Associate Director, Principal Investigator, Viral Persistence Section, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research 
• 3-3:25 p.m., Advancements in Clinical Development of Lenacapavir
  Laurie VanderVeen, Director, HIV Clinical Virology, Gilead Sciences 
• 3:30-4:30 p.m., Networking Opportunity (refreshments provided)

Session 4: Treatment of HIV Infection: State of the ART

Session Moderator:  Eric Freed, Senior Investigator and Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute

• 7:30-8 a.m., Networking
  Continental breakfast will be provided
• 8-8:25 a.m., PEPFAR at 20
  Nelson L. Michael, Director, Center for Infectious Disease Research, Walter Reed Army Institute of Research
• 8:30-8:55 a.m., HIV Prevention, Treatment and Cure: Pushing the Limits of Antiretroviral Therapy
  Steven Deeks, Professor of Medicine, University of California San Francisco, Faculty Member, Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital
• 9-9:25 a.m., Antiretroviral Drug Resistance in 2024
  Frank Maldarelli  Senior Investigator and Head, Clinical Retrovirology Section, HIV Dynamics and Replication Program, National Cancer Institute
• 9:30-9:55 a.m., Chronic Inflammation and Co-morbidity in Treated HIV Infection
  Peter W. Hunt, Professor of Medicine, University of California San Francisco Associate Chief for Research, ZSFG-UCSF Department of Medicine, Department of Medicine, Division of Experimental Medicine
• 9:55-10:10 a.m., Break

Session 5: CNS Infection in HIV; KSHV

Session Moderator: Denise Whitby, Senior Principal Scientist, Viral Oncology Section, AIDS and Cancer Virus Program, Frederick National Laboratory

• 10:10-10:35 a.m., CNS Infection with HIV
  Sarah Joseph, Assistant Professor, University of North Carolina School of Medicine, Microbiology and Immunology
• 10:40-11:05 a.m., KSHV/KS Epidemiology in the Southern US
  Elizabeth Yu Chiao, M.D., MPH, Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
• 11:10-11:35 a.m., Insights on the Pathogenesis and Treatment of KSHV-Associated Tumors and Other Diseases
  Robert Yarchoan, Chief, HIV and AIDS Malignancy Branch, Center for Cancer Research, Director, Office of HIV and AIDS Malignancy, National Cancer Institute 
• 11:40 a.m.-12:05 p.m., Patient-derived Xenografts of Kaposi Sarcoma Are a Novel Model to Inform Therapeutic Targets Against Virus-driven Processes
  Laurie T. Krug, Stadtman Investigator, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
• 12:05-1:30 p.m., Lunch

Session 6: HIV Rebound Competent Viral Reservoir and Towards a Cure

Session Moderator: Brandon Keele, Senior Principal Scientist and Associate Director, AIDS and Cancer Virus Program, Frederick National Laboratory

• 1:30-1:55 p.m., Molecular Characteristics and Pathogenesis of the Persistent HIV Reservoir
  Robert Siliciano, Professor, Johns Hopkins School of Medicine, Investigator, Howard Hughes Medical Institute
• 2-2:25 p.m., Leveraging Advances in mRNA to Target the HIV Reservoir
  Sharon Lewin, Director, The Peter Doherty Institute for Infection and Immunity, Professor of Medicine, The University of Melbourne
• 2:30-3:30 p.m., Panel Discussion: Moderator - Sandhya Vasan, Director, HJF, Military HIV Research Program and Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Vice President, Global Infectious Diseases Research
  • Mike McCune, Head, HIV Frontiers, Bill & Melinda Gates Foundation
  • Mike Saag, Professor of Medicine-Infectious Diseases, University of Alabama at Birmingham
  • Lynda Dee, Community Engagement Coordinator DARE MDC AIDS Action Baltimore, Executive Director
  • John Coffin, Tufts University School of Medicine
• 3:30 p.m., Closing Remarks (meeting summary, vision for the future of HIV)
  • Jeff Lifson, Director, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research
  • Mary Carrington, Director, Basic Science Program, Frederick National Laboratory for Cancer Research